A recent study revealed that concurrent inhibition of PD-L1, CXCR1/2, and TGF-β significantly augmented T-cell infiltration and activation in the tumor microenvironment, consequently enhancing the antitumor activity of ICI (33). The gene discussed is TGFB1; the disease is neoplasm.